Skip header and navigation

1 records – page 1 of 1.

Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?

https://arctichealth.org/en/permalink/ahliterature142078
Source
Eur Arch Psychiatry Clin Neurosci. 2011 Mar;261(2):95-102
Publication Type
Article
Date
Mar-2011
Author
Ari Illi
Outi Poutanen
Eija Setälä-Soikkeli
Olli Kampman
Merja Viikki
Heini Huhtala
Nina Mononen
Susann Haraldsson
Pasi A Koivisto
Esa Leinonen
Terho Lehtimäki
Author Affiliation
Medical School, University of Tampere, 33014 Tampere, Finland. ari.illi@uta.fi
Source
Eur Arch Psychiatry Clin Neurosci. 2011 Mar;261(2):95-102
Date
Mar-2011
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Chi-Square Distribution
Depressive Disorder, Major - drug therapy - genetics
Female
Finland
Genome-Wide Association Study
Genotype
Humans
Male
Middle Aged
Pharmacogenetics
Polymorphism, Genetic - genetics
Psychiatric Status Rating Scales
Serotonin Plasma Membrane Transport Proteins - genetics
Serotonin Uptake Inhibitors - therapeutic use
Young Adult
Abstract
The role of a functional polymorphism in the transcriptional control region of serotonin transporter gene (5-HTTLPR, SERTPR) has been studied intensively in major depression and in the response to selective serotonin inhibitors (SSRIs) in major depression. The findings have been contradictory, although majority of the studies indicate that the short allele is associated with poor response to SSRIs in major depression. In the present study, we evaluated the association of 5-HTTLPR with treatment response to SSRI medication in Finnish Caucasian MDD patients. A secondary purpose was to study the possible association of this particular polymorphism with major depressive disorder. The aim of the study was to replicate the previous findings in this area. Primary outcomes of the treatment were remission, defined by an exit score of seven or less, and response, defined by a reduction of at least 50% on the MADRS. We had also a control population of 375 healthy blood donors, as a secondary objective was to evaluate the possible association of this particular polymorphism with major depressive disorder. Twenty-nine of the 85 (34.1%) patients reached the remission and 58.8% achieved the predefined response criteria. The l/l genotype of 5-HTTLPR was presented in 51.7% of those patients who achieved remission vs. 25.0% in the non-remitters (P = 0.03). The result remained statistically significant after adjusting for age, gender, medication and MADRS points at the study entry. However, the small sample size limits the reliability of this result.
PubMed ID
20640435 View in PubMed
Less detail